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Abstract
Respiratory insufficiency is the major cause of morbidity and mortality in patients affected by
cystic fibrosis. An excessive neutrophilic inflammation, mainly orchestrated by the release of IL-8
from bronchial epithelial cells and amplified by chronic bacterial infection with Pseudomonas
aeruginosa, leads to progressive tissue destruction. The anti-inflammatory drugs presently utilized
in cystic fibrosis patients have several limitations, indicating the need for identifying novel
molecular targets. To address this issue, we preliminarily studied the association of 721 single-
nucleotide polymorphisms from 135 genes potentially involved in signal transduction implicated
in neutrophil recruitment in a cohort of F508del homozygous cystic fibrosis patients with either
severe or mild progression of lung disease. The top ranking association was found for a
nonsynonymous polymorphism of the phospholipase C beta 3 (PLCB3) gene. Studies in bronchial
epithelial cells exposed to P.aeruginosa revealed that PLCB3 is implicated in extra cellular
nucleotide–dependent intracellular calcium signaling, leading to activation of the protein kinase C
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alpha and beta and of the nuclear transcription factor NF-κB p65. The pro-inflammatory pathway
regulated by PLCB3 acts by potentiating the Toll-like Receptors’ signaling cascade and represents
an interesting molecular target to attenuate the excessive recruitment of neutrophils without
completely abolishing the inflammatory response.
Introduction
Cystic fibrosis (CF), an autosomal-recessive disease manifesting progressive respiratory
insufficiency, defective exocrine pancreatic secretion and elevated electrolyte concentration
in the sweat, is related to loss-of-function mutations of the CF Transmembrane conductance
Regulator (CFTR) gene encoding a chloride transporting protein (OMIM 219700).
The major cause of morbidity and mortality of CF patients is chronic lung disease.
Innovative therapies to prevent the onset or reduce the pulmonary damage are under
intensive pre-clinical and clinical investigation (1). Besides pharmaceutical approaches to
correct the mutated CFTR protein and potentiate its ion transport function, novel anti-
inflammatory drugs will be particularly relevant to those adolescent and adult CF patients
who have already developed lung pathology (2). However, current anti-inflammatory drugs,
such as corticosteroids, show limitations in terms of efficacy or occurrence of adverse
effects in CF patients, suggesting the need of identifying novel molecular targets and more
effective anti-inflammatory drugs specifically tailored for CF pulmonary pathophysiology
(2).
A hallmark of lung pathology in CF is a neutrophil-dominated inflammation, which is
disproportionate to the bacterial infection, typically by Pseudomonas aeruginosa. Excessive
infiltrates of neutrophils, releasing proteases upon continuous activation by bacterial
products, are presently thought to play a major role in the progressive destruction of the CF
lung tissue (3, 4). The chemokine Interleukin (IL)-8 is the most abundant soluble mediator
recruiting neutrophils in the bronchi of CF patients, being found in the airway secretions
both in advanced and in early stages of the disease (5–7). Interestingly, IL-8 promoter
variant alleles resulting in reduced expression of IL-8 protein are protective in respect to the
severity of progression of lung disease in CF patients (8), supporting the concept that
reduction of the excessive IL-8-driven neutrophil recruitment could be a relevant
pharmacological objective to ameliorate CF pulmonary disease.
A major source of IL-8 release in CF lungs are the bronchial epithelial cells lining the
conductive airways of CF patients (9, 10). Binding of bacterial components to pattern-
recognition receptors expressed on epithelial cell surface, such as Toll-like receptors
(TLRs)-2, 4 and 5, activates a series of kinases and adapters, ultimately triggering nuclear
translocation of transcription factors and expression of pro-inflammatory genes (11). In
addition, interaction of P.aeruginosa with AsialoGM1 receptor (ASGM1R), which
colocalizes with TLR5, promotes sustained release of nucleotides (12, 13). Extra cellular
ATP, through an autocrine binding to the seven-membrane spanning domain P2Y2
purinergic receptor, activates cytosolic calcium signaling and contributes, together with
TLRs, to the expression of IL-8 (14).
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Due to the high redundancy in receptors and downstream signaling components triggered by
P.aeruginosa in bronchial epithelial cells, finding key targets to effectively reduce excessive
inflammatory response represents a major challenge. To prioritize the investigation on key
target molecule(s) intervening in this pro-inflammatory network, we performed a pilot
genotype-phenotype association study between variants of genes involved in the innate
immune response and the severity of lung disease in CF patients. So far, association studies
have highlighted that the mannose-binding lectin 2 (MBL2), the Transforming Growth
Factor - beta 1 (TGFB1) and the IFRD1 genes can modulate the progression of lung disease
in CF (15–17). Thus, to start identifying critical components modulating the inflammatory
signaling cascade triggered by P.aeruginosa in bronchial epithelial cells, we studied the
distribution of allelic variants of 721 Single Nucleotide Polymorphisms (SNP) from a panel
of 135 genes of innate immunity in two groups of CF patients characterized by severe or
mild progression of lung disease. By ranking the association of each SNP with the
progression of lung disease severity, we found on the top a non-synonymous polymorphism
of the phospholipase C beta 3 (PLCB3) gene, leading to investigate firstly the role of the
PLCB3 enzyme. Functional studies performed in human bronchial epithelial cells exposed
to P.aeruginosa demonstrate that PLCB3, by regulating intracellular calcium transients,
plays a relevant role in amplifying the expression and release of IL-8, the major chemokine
recruiting neutrophils in CF airway lungs.
Materials and Methods
Materials
The calcium chelator BAPTA-AM was from Molecular Probes (Eugene, OR), the broad
protein kinase C inhibitor bisindolylmaleimide (BIM)-I was from Merck KGaA (Darmstadt,
Germany), all the other reagents were from Sigma, unless otherwise indicated.
Subjects
DNA samples were collected from CFTR F508del homozygous patients enrolled by the
University of North Carolina at Chapell Hill, Chapel Hill (M.R.K.) and by Case Western
Reserve University, Cleveland (M.L.D.). CF patients were classified as “mild” (n=300) or
“severe” (n=208) with respect to the progression of lung disease according to the FEV1
measurements, according to the criteria reported previously by the North American Gene
Modifier Study Group (GMSG) (16). The study was approved by the institutional review
boards (IRB) of the participating institutions collecting the samples from patients affected
by cystic fibrosis.
Selection of SNPs
Different types of SNPs have been chosen in candidate genes, using the HapMap database.
In particular, two different types of polymorphisms have been chosen: 1) nonsynonymous
coding SNPs (nsSNPs) that include a group of SNP having the highest impact on phenotype
for their potential to directly affect the structure, function and interactions of expressed
proteins and 2) Tag SNPs, which represent a subset of SNPs capturing most of the haplotype
diversity of each haplotype block or gene-specific region. Tag SNPs have been selected
using Tagger, a software implemented in Haploview (http://www.broad.mit.edu/mpg/
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haploview/). Genotype data in raw Hap Map format have been uploaded in order to specify
the genomic regions of interest within which tag SNPs to be picked. As output, Tagger
produced a list of tag SNPs and corresponding statistical tests to capture all variants of
interest, and a summary coverage report of the selected tag SNPs.
Genotyping by Illumina technology
Analysis of SNPs has been firstly performed by Illumina technology. An overall number of
721 SNPs was selected within 135 genes and analyzed using the “Custom Golden-Gate
Genotyping" (http://www.illumina.com) assay on ILLUMINA platform. This genotyping
system consisted of an initial allele-specific extension reaction followed by PCR
amplification. Amplified products were hybridized to an array matrix of bead-based probe
sequences where each bead is coated with universal probes and represented multiple times
for increased accuracy (average of 25 times).
Genotyping by Taqman technology
Genotype of the SNPs ranking on top of statistical significance have been verified with
Taqman assays from Applied Biosystems. All reactions utilizing TaqMan MGB probes were
run under standard condition on an ABI PRISM® 9700 HT system. Genotyping of
phospholipase C SNPs in the human bronchial epithelial cell lines IB3-1 and CuFi-1 was
performed by both Taqman technology and direct sequencing (see Supplemental Tables 5
and 6).
Human bronchial epithelial cell culture
IB3-1 cells (LGC Promochem Europe) are human bronchial epithelial cells immortalized
with adeno12/SV40, derived from a CF patient with a mutant F508del/W1282X genotype
(18). Cells were grown in LHC-8 basal medium (Biofluids, Rockville, MO) supplemented
with 5% fetal bovine serum (FBS). All culture flasks and plates were coated with a solution
containing 35 mg/ml bovine collagen (Becton-Dickinson, Franklin Lakes, NJ), 1 µg/ml BSA
(Sigma-Aldrich, St. Louis, MO) and 1 µg/ml human fibronectin (Becton-Dickinson) as
previously described. CuFi-1 cells were a generous gift from A. Klingelhutz, P. Karp and J.
Zabner (University of Iowa, Iowa City, IO). CuFi-1 cells were derived from human
bronchial epithelia from a patient with CF (CFTR mutant genotype F508del/F508del) and
transformed by reverse transcriptase component of telomerase, hTERT, and human
Papillomavirus type 16 (HPV-16), E6 and E7 genes (19). These cells were grown on human
placental collagen type IV (Sigma-Aldrich, St. Louis, MO)-coated flasks in bronchial
epithelial growth medium (BEGM) (Cambrex Bioscience, Walkersville, MD), as previously
described (19). CuFi-1 cells were seeded onto cell culture inserts (pore size of 0.4 µm) in
Falcon 24-well multitrays (BD Biosciences, Franklin Lakes, NJ) at a density of 7 × 105
cells/insert and grown in BEGM for 15 days. Transepithelial electrical resistance (TER) was
measured with an epithelial voltometer (EVOM; World Precision Instruments, Sarasota,
FL). The cell inserts were used for experiments when the cell monolayers reached a TER>
1000 Ω x cm2.
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Infection with P.aeruginosa bacterial strains
The well-characterized motile nonmucoid laboratory strains of P.aeruginosa named PAO1,
PAK, PAK FliC (recombinant P.aeruginosa strain PAK lacking expression of flagellin)
have been kindly donated by A. Prince (Columbia University, New York, NY). Bacteria
colonies from overnight cultures on trypticase soy agar (TSA) (Difco, Detroit, MI) plates
were grown with shaking in 20 ml of trypticase soy broth (TSB) (Difco) at 37°C until an
optical density (A660 nm wavelength), corresponding to 1 × 107 colony-forming units
(CFU)/ml, was reached. Bacteria were washed twice with PBS and diluted in each specific
serum-free medium before infection and added to cells at the concentration indicated as
CFU/cell.
Expression of phospholipase C isoforms and of IL-8
PLC and IL-8 transcripts were quantified Real-Time Polymerase Chain Reaction (qRT-
PCR) as previously described (20). Briefly, total RNA from cells was isolated using High
Pure RNA Isolation Kit (Roche, Mannheim, Germany). 2 µg of total RNA was reverse-
transcribed to cDNA using the High Capacity cDNA Archive Kit and random primers
(Applied Biosystems, Foster City, CA) in a 100-µl reaction. The cDNA (2 µl) was then
amplified for 40 PCR cycles using the SYBR® Green PCR Master Mix (Applied
Biosystems, Foster City, CA) in a 10-µl reaction using 7900HT Fast Real-Time PCR
apparatus (Applied Biosystems, Foster City, CA). The qRT-PCRs were performed in
duplicates for both target and normalizer genes. Primer sequences and concentration are
shown in Supplemental Table S4. Primer sets were purchased from Integrated DNA
Technologies (Tema Ricerca s.r.l., BO, Italy). Relative quantification of gene expression
was performed using the comparative threshold (CT) method as described by the
manufacturer (Applied Biosystems User Bulletin 2). Changes in mRNA expression level
were calculated after normalization to calibrator gene. The ratios obtained after
normalization are expressed as fold changes over untreated samples for IL-8 mRNA and for
the relative expression of the housekeeping gene Human Cytokeratin (HCK)-15 for the
isoforms of phospholipase C. PLCB3 protein was detected by immunofluorescence. IB3-1
cells were seeded on eight-well chamber slides (Nunc, Naperville, IL) and pre-incubated
with PLCB3 siRNA or scrambled duplexes for 24 hours in LHC-8 basal serum-free medium
as indicated below in the silencing protocol. Cells were washed three times with PBS and
fixed with 4% paraformaldehyde (wt/vol) in PBS for 20 minutes at room temperature. After
three washes with PBS, cells were permeabilized with methanol at −20°C for 5 minutes and
dried for 1 hour. Slides were incubated with 5% bovine serum albumin (BSA) in PBS for 90
minutes at room temperature and then subjected to three incubations at room temperature
with: a) 1:200 dilution of rabbit polyclonal antibody anti-PLCB3 (sc-13958 from Santa Cruz
Biotechnology, Santa Cruz, CA) in 5% BSA for 1 hour or with an irrelevant rabbit IgG
antibody; b) 1:200 dilution of biotinylated goat anti-rabbit immunoglobulin G (Santa Cruz
Biotechnology) in 1% BSA–PBS–0.1% Tween 20; c) 1:60 dilution of fluorescein
isothiocyanate conjugated streptavidin (Sigma) in 1% BSA–PBS–0.1% Tween 20.
Coverslips were mounted with Prolong Antifade (Molecular Probes, Eugene, OR) and stored
at room temperature. Fluorescence was examined with a digital imaging system based on a
Zeiss Axiovert 200 fluorescence microscope equipped with a back-illuminated CCD camera
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(Roper Scientific, USA), excitation and emission filter wheels (Sutter Instrument Company,
USA) and piezoelectric motoring of the z stage (Physik Instrumente, GmbH & Co.,
Germany) for rapid focussing in the Z plane. The data were acquired and processed using
the MetaMorph analyzing program (Universal Imaging Corporation, USA). The Z-steps
were then turned into projections and the average intensity after background subtraction was
determined. All intensity comparisons were determined from at least 10 different cells to
minimise cell-to-cell staining variations. The levels of PLCB3-silencing were was expressed
as % of arbitrary unit of fluorescence (F.A.U.), in respect to scrambled condition. IL-8
protein release was measured with an ELISA assay. IB3-1 and CuFi-1 cells were grown and
infected as described, then supernatants were collected from each well and an enzyme-
linked immunosorbent assay for the quantitative detection of human IL-8 was performed
using the Human IL-8 Instant ELISA kit (Bender Med Systems, Vienna, Austria) according
to the manufacturer’s protocol.
Silencing PLCB3 gene
To perform silencing experiments of PLCB3 gene a TriFECTa RNAi Kit (Integrated DNA
technologies, Coralville, Iowa, IA) was used accordingly to the manufacturer’s instructions.
IB3-1 cells were transiently transfected with specific small-interfering RNA (siRNA) for
PLCB3 (sequence 1: AGAUGAGGGACAAGCAUAAGAAGGA; sequence 2:
GCUCGAAAGAGGAACCGAAGCAUUUGUUCCU) or scrambled (sequence
CUUCCUCUCUUUCUCUCCCUUGUGA) duplexes complexed with cationic liposomes
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Lipofectamine 2000 (4 µl) was diluted in 1
ml LHC-8 serum-free cell culture medium. PLCB3 siRNA or scrambled duplexes (10 nM)
were added and incubated for 10 minutes. Liposome: duplexes complexes in LHC-8 serum-
free medium (500 µl) were added to IB3-1 cells grown in 2-cm2 wells and incubated at
37°C/5% CO2 for 6 hours. Cells were washed twice with culture medium and left at
37°C/5% CO2 for a further 18 hours.
Activation of NF-kB
IB3-1 cell nuclear extracts were prepared as previously described (20). Briefly, IB3-1 cells
were transfected with PLCB3 siRNA or scrambled duplexes for 24 hours and stimulated
with P.aeruginosa, PAO1 strain (100 CFU/cell) for a further 1, 2 or 4 hours, washed twice
with iced PBS and detached by trypsinization. Nuclear proteins were separated by hypotonic
lysis followed by high-salt extraction treatment of nuclei. A quantitative NF-kB p65 subunit
capture assay was performed by Trans AM NF-kB p65 Activation Assay (Active Motif,
Carlsbad, CA) using 2.5 µg of nuclear extracts for each sample, according to the
manufacturer’s instructions. Briefly, nuclear extracts were added to wells coated with an
oligonucleotide containing a NF-kB consensus binding site. The binding was revealed by
subsequent addition of a primary antibody directed against p65 and a secondary antibody
conjugated to horseradish peroxidase and, after the addition of the substrate, absorbance was
read at 450 nm wavelength.
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Purification of flagellin and pilin from P.aeruginosa
Purification of flagellin was performed as described (21) starting from the PAK/NP
recombinant P.aeruginosa strain lacking expression of pilin. Pilin proteins were isolated
using the method of Castric (22), starting from the PAK/fliC recombinant P.aeruginosa
strain lacking expression of flagellin.
Fura-2/AM measurements
The cytosolic free Ca2+ concentration was evaluated using the fluorescent Ca2+ indicator
Fura-2 acetoxymethyl ester (Fura-2/AM; Molecular Probes). Briefly, cells were incubated in
medium supplemented with 2.5 µM Fura-2/AM for 30 min, washed with KRB buffer to
remove the extra cellular probe, supplied with preheated KRB buffer (supplemented with 1
mM CaCl2), and placed in a thermostated (37 °C) incubation chamber of an LS50 Perkin
Elmer fluorometer (Perkin Elmer Ltd., Beaconsfield, UK). Fluorescence was measured
every 100 ms with the excitation wavelength alternating between 340 and 380 nm and the
emission fluorescence being recorded at 510 nm. The [Ca2+]i was calculated by the ratio
method using the equation: [Ca2+]i= Kd*(R-Rmin)/(R-Rmax)*Sf2/Sf1 where Kd is
dissociation constant of Fura-2/AM for (Ca2+) taken as 240 nM at 37 °C, R is ratio of
fluorescence for Fura-2/AM at the two excitation wavelengths, F340/F380, Rmax is ratio of
fluorescence in the presence of excess of calcium obtained by lysing the cells with 10 µM
ionomycin (Sigma Aldrich), Rmin is ratio of fluorescence in the presence of minimal
calcium obtained by lysing the cells and then chelating all the Ca2+ with 0.5 M EGTA, Sf2
is fluorescence of Ca2+ free form of Fura-2/AM at 380nm excitation wavelength and Sf1 is
fluorescence of Ca2+ bound form of Fura-2/AM at 380 nm excitation wavelength. IB3-1
cells were transfected and stimulated with P.aeruginosa, PAO1 strain (100 CFU/cell), as
reported in the figures.
Aequorin measurements
The probes employed (cytAEQ, erAEQmut and mtAEQ) are chimeric aequorins targeted to
the cytosol, endoplasmic reticulum and mitochondria, respectively (23). For the experiments
with cytAEQ and mtAEQ, cells were incubated with 5 µM coelenterazine for 1–2 h in
modified KRB supplemented with supplemented with 1 mM CaCl2. Then the cover slip with
transfected cells was placed in a perfused, thermostated chamber located in the close
proximity of a low noise photomultiplier, with a built-in amplifier-discriminator. To
reconstitute the erAEQmut with high efficiency, the luminal [Ca2+] of the ER first had to be
reduced. This was achieved by incubating the cells for 1 h at 4°C in KRB supplemented
with 5 µM coelenterazine, the Ca2+ ionophore ionomycin, and 600 µM EGTA. After this
incubation, cells were extensively washed with KRB supplemented with 2% bovine serum
albumin and then transferred to the perfusion chamber. All aequorin measurements were
carried out in KRB supplemented with either 1 mM CaCl2 (cytAEQ and mtAEQ) or 100µM
EGTA (erAEQmut). Agonist, as Histamine 100 µM, and other drugs were added to the same
medium, as showed in the figures. The experiments were terminated by lysing the cells with
100 µM digitonin in a hypotonic Ca2+-containing solution (10 mM CaCl2 in H2O), thus
discharging the remaining aequorin pool. The output of the discriminator was captured by a
Thorn-EMI photon counting board and stored in an IBM-compatible computer for further
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analyses. The aequorin luminescence data were calibrated off-line into [Ca2+] values, using
a computer algorithm based on the Ca2+ response curve of wildtype and mutant aequorins.
Chemicals and reagents were from Sigma or from Merck except for coelenterazine and
coelenterazine n, which were from Molecular Probes
Microscopic analysis of PKC translocation
Images of PKC translocation were recorded using a digital imaging system based on a Zeiss
Axiovert 200 fluorescence microscope. The data were acquired and processed using the
MetaMorph analysis program (Universal Imaging Corporation, USA). For computational
deblurring, a stack of images through the z plane was acquired (200 ms/image; 20 plans 0.5
µm apart) and processed using the EPR software developed by the Biomedical Imaging
group of the University of Massachusetts Medical School (Worcester, MA, USA).
Microscope analysis were performed 36 h after transfection. The medium was changed from
LHC-8 basal medium + 5% FCS to KRB. P.aeruginosa strain, and other drugs (phorbol
ester PMA 400nM and Apyrase 3 U/ml, respectively) were added to the buffer, as showed in
the figures. The recruitment of the kinases are represented as plasma membrane
translocation of different PKC–GFP chimeras, expressed as the increase in fluorescence
ratio with respect to time 0 (calculated as the ratio of plasma membrane and cytosol average
intracellular fluorescence, obtained from multiple regions inside the cytosol and on the cell
membrane, measured on single cell). The graphs (figure 5) indicate the levels of PKC
translocation, expressed as the fluorescence ratio, to plasma membrane (for PKCα, PKCβ
and PKCδ) or nucleus (for PKCζ), on the average of cytosolic fluorescence intensity.
Statistical methods
For association between disease and single SNPs, test for allelic association (which
compares frequencies of alleles in cases versus controls) have been utilized. For these
analyses, permutation tests (ie, permuting the phenotypes) have been conducted in order to
account for the large numbers of tests. Our analyses have been performed using PLINK
(http://pngu.mgh.harvard.edu/~purcell/plink/) and R (http://www.r-project.org/). After
validation of Illumina genotype screening by Taqman assay, allelic associations have been
tested with chi-square test. Student’s t test has been applied to the experiments performed in
human bronchial epithelial cells with statistical significance at p<0.05 (*) or p<0.01 (**)
levels.
Results
Association of PLCB3 gene with the progression of lung disease in CF
A panel of genes of the innate immunity has been chosen as candidate modulators of the
proinflammatory signaling elicited by P.aeruginosa in bronchial epithelial cells
(Supplemental Table S1). They included 135 genes, such as those encoding chemokines and
adhesion molecules, pattern-recognition receptors (PRRs) sensing the presence of bacteria in
the lumen of the conductive airways and several components of the signaling network acting
downstream the PRRs. To choose in each gene those allelic variants most probably
contributing to changes in expression or function of the encoded proteins, due to the large
series of Single Nucleotide Polymorphisms (SNPs) reported for each of these genes, we
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selected firstly all those SNPs resulting in non-synonymous changes in the coding regions
and, secondly, those TagSNPs in intronic, 3’- and 5’- untranslated regions that mark the
haploblocks composed of several single SNPs, for a total of 721 SNPs, as listed in the
Supplemental Table S2. DNA samples were from a representative cohort of 508 CF patients
selected by the North American Gene Modifier Study Group (GMSG) and classified as
having either severe (n = 200) or mild (n = 308) progression of lung disease, according to
the criteria described previously (16). Genotyping the 721 SNPs has been firstly performed
using Illumina platforms with individual 508 DNA samples. The top-ranking group of SNPs
showing significant genotype-phenotype association was subsequently validated with
Taqman probe assays. By ranking the association between variant alleles and the severe or
mild groups of CF patients, 26 SNPs showed a statistical significance with P values < 0.05,
as calculated by permutation test (Supplemental Table S3). Interestingly, within the top-
ranking list of the 721 SNPs, five of them were variants of phospholipase C (PLC) isoforms
beta, namely a nonsynonymous SNP of the PLC isoform beta 3 gene (PLCB3), three
intronic Tag SNPs of the PLC isoform beta 1 gene (PLCB1) and one intronic Tag SNP of
the PLC isoform beta 4 gene (PLCB4). The C2534T variant (rs35169799) of the
phospholipase C beta 3 (PLCB3) gene was found on top of the rank of the 721 SNPs. The
minor allele T was found significantly associated with the milder CF phenotype group (Chi-
square test value = 8.01, permutation test P value = 0.0046) (Table 1). Milder CF patients
were associated with the minor 2534T allele with O.R. = 2.297 (C.I. 95% = 1.27 – 4.14), as
shown in Table 2. The C2534T variant encodes a non-synonymous serine to leucine change
in the amino acid residue at position 845, which is localized in the C-terminal tail in close
proximity to the C2 domain of the PLCB3 protein (24, 25). These two domains are known to
be involved in the interaction with Gaq/11 heterotrimeric GTPase protein and in the
anchoring of PLCB3 to the plasma membrane through salt-like Ca2+ bonds, respectively
(24, 25).
Silencing PLCB3 reduces the expression of IL-8 chemokine
PLC beta isoforms are implicated in signal transduction by receptors for hormones, growth
factors, neurotransmitters and other ligands involved in regulation of different cellular
processes, including the immune response (25). Although human bronchial epithelial cells
express, albeit at different levels, the transcripts of all the PLC beta isoforms, (Supplemental
Figures S5 and S2), we focused our attention on PLCB3, since it is the most highly
expressed within the beta isoforms and it is the top-ranking gene associated with clinical
phenotype. To understand whether PLCB3 could be relevant in the induction of IL-8 in
respiratory cells exposed to bacterial infection, we studied the transcription and release of
IL-8 after silencing the expression of endogenous PLCB3 with siRNA oligonucleotides in
human bronchial epithelial cells from cystic fibrosis patients exposed to P.aeruginosa. The
bronchial cell lines utilized were all homozygous for the major allele of the PLCB3 C2534T
variant (S845), as reported in Supplemental Table 5. Transfection of two different duplexes
PLCB3 siRNA reduced significantly, albeit partially, the levels of expression of PLCB3
mRNA (Fig. 1A) and protein (Fig.1B–E), as detected by quantitative RT-PCR and confocal
immunofluorescence, respectively. No significant reduction of transcript levels of PLC
isozymes beta 1, 2 and 4 was observed with PLCB3 siRNA in IB3-1 cells (Supplemental
Figure S1). Infection with P.aeruginosa did not change significantly the levels of PLCB3
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mRNA. In the same experimental model, partial silencing of PLCB3 produced a parallel
reduction of IL-8 transcription and release in IB3-1 cells exposed to P.aeruginosa (Fig. 1 F
and H), without changing the basal IL-8 mRNA levels in uninfected cells. Silencing PLCB3
did reduce the IL-8 transcription and release induced by flagellin, a component of
P.aeruginosa interacting with TLR5, but did not affect the TNF-α-dependent IL-8
expression (Fig. 1 G and H), suggesting that PLCB3 may have a role in downstream
signaling of TLR5 but not TNFRs. The effect of silencing PLCB3 gene seems mainly
restricted to IL-8, since the expression of other genes induced by P.aeruginosa in bronchial
epithelial cells, such as ICAM-1, GRO-γ, IL-6 and TNF-α, is not reduced (Fig 1 I). The
reduction of IL-8 expression after silencing PLCB3 was confirmed in the CF human
bronchial epithelial cell lines CuFi-1 grown polarized on Transwell filters, after exposure to
P.aeruginosa on the apical side (Fig. 2). These results provide the first evidence that PLCB3
could be one of the components of a signaling network involved in the expression of IL-8 in
human bronchial epithelial cells exposed to P.aeruginosa.
PLCB3 is implicated in Ca2+-related signaling and activation of protein kinase C (PKC)
alpha and beta
Like the other phospholipase C (PLC) isoforms, PLCB3 catalyzes the hydrolysis of
phosphatidylinositol 4,5-biphosphate (PIP2) to generate two second messengers,
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which in turn activate
intracellular calcium transients (24, 25). Notably, it has been recently shown that PLCB3 is a
critical regulator of intracellular Ca2+ in murine macrophages (26). Exposure of IB3-1 cells
to P.aeruginosa induced a sustained increase of cytosolic Ca2+ concentration ([Ca2+]c) as
measured using fura-2 technique (Fig. 3A). Conversely, buffering the increase of [Ca2+]c
with the intracellular Ca2+-chelator BAPTA reduced significantly the induction of IL-8
mRNA (Fig. 3B), as already reported by other investigators (13, 27). BAPTA further
reduced the IL-8 mRNA expression in cells silenced for PLCB3 (Fig 3C), but in BAPTA-
loaded cells PLCB3 silencing did not reduce IL-8 expression below the level detected in
cells treated with the control siRNA. These findings suggest two set of conclusions. Firstly,
that in our experimental model calcium signaling is not completely mediated by PLCB3.
Notably, IB3-1 and CuFi-1 bronchial epithelial cells express different PLC isoforms besides
the beta ones, in particular PLCγ2, PLCδ3 and PLCε1, which could participate in activation
of calcium transients (Supplemental Figure S2). Secondly, that silencing of PLCB has an
effect only because it reduces calcium signaling because in cells in which calcium is
chelated by BAPTA no further reduction of IL-8 expression is induced by PLCB3 siRNA.
The role of PLCB3 in intracellular Ca2+ signaling upon interaction of P.aeruginosa with
bronchial epithelial cells was studied in some details. The [Ca2+]c increase promoted by
P.aeruginosa was reduced in IB3-1 cells pre-incubated with PLCB3 siRNA (Fig. 4A),
although not completely, possibly due to a parallel partial reduction of PLCB3 expression.
By inducing [Ca2+]c transients with histamine (causing the generation of inositol 1,4,5
trisphosphate and the consequent release of Ca2+ from the endoplasmic reticulum, ER) in
IB3-1 cells expressing the intracellular organelle-targeted Ca2+-sensitive aequorins, no
difference in ER Ca2+ uptake was observed between silenced PLCB3 and control cells.
Indeed, both groups of cells showed very similar luminal ER Ca2+ concentrations ([Ca2+]er)
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at rest (see left part of Fig. 4B). On the contrary, we found that silencing PLCB3 reduces the
release of Ca2+ from the ER (right part of Fig. 4B and C). Accordingly, the transient rises of
[Ca2+]c and in the mitochondrial matrix ([Ca2+]m) elicited by the agonist were smaller in
silenced PLCB3 cells compared to control cells (Fig. 4 D and E). Signals that elevate
intracellular Ca2+ and DAG, such as those induced by PLCs, are known to activate
conventional protein kinase C (PKC) isoforms (28). Activation of PKC was studied by
observing the translocation of the recombinant GFP-tagged Ca2+- dependent conventional
PKC isoforms alpha and beta to the plasma membrane in IB3-1 cells infected with
P.aeruginosa. Bacterial exposure induced activation of the conventional PKC isoforms
alpha and beta (Fig. 5 A and B), but not of the novel delta isoform (Fig. 5C) and of the
atypical zeta isoform (Fig. 5D), the most striking effect being observed for PKC beta, where
an average 56.1% of the cells showed membrane translocation. By silencing PLCB3
expression, the activation of PKC beta was abrogated in the majority of the IB3-1 cells (Fig.
6A and B), a residual PKC beta activation being observed only in an average 12.0 % of cells
exposed to P.aeruginosa. The role of PKC activation in the P.aeruginosa-but not TNF-α-
dependent signaling of our experimental model has been also confirmed by the effect of the
broad PKC inhibitor bisindolylmaleimide (BIM)-I (Fig. 6C). It has been previously shown
that P.aeruginosa PAO1 strain activates a Ca2+-dependent activation of the transcription
factor NF-kB, which is critical in the regulation of IL-8 gene transcription also in human
airway epithelial cells (27). Therefore, we tested the role of PLCB3 on the activation of NF-
kB p65 induced by PAO1 in IB3-1 cells, with a time-course preceding the lapse of time of 4
hrs chosen to measure IL-8 mRNA levels. We confirm that PAO1 progressively activates
NF-kB and that silencing PLCB3 significantly reduces the P.aeruginosa-induced activation
of NF-kB p65 (Fig. 6D). Collectively, these results indicate that PLCB3 plays a relevant role
in triggering free calcium transients induced by P.aeruginosa in human bronchial epithelial
cells, thus regulating the activation of the PKCs alpha and beta and of the nuclear
transcription factor NF-kB.
Extra cellular ATP is not sufficient for IL-8 expression but acts in synergy with TLRs
Interaction of P.aeruginosa with ASGM1R, colocalized with TLR5, is known to promote
the release of nucleotides from epithelial cells, activating an autocrine loop with P2Y2
receptors (12, 13). Interestingly, PLCB3 has been shown to be selectively coupled to the
P2Y2 receptor-dependent activation of intracellular Ca2+ transients in recombinant CHO
cells (29). The role of different ligands on the expression of IL-8 has been preliminarily
tested. IL-8 transcription was induced, albeit at different extents, after exposing IB3-1 cells
to intact P. aeruginosa bacteria of strains PAO1 and PAK, to the purified P.aeruginosa
bacterial components flagellin and pilin, and to the pro-inflammatory cytokine TNF-α (Fig.
7A). PAK FliC, a recombinant P.aeruginosa PAK strain lacking expression of flagellin,
induces IL-8 expression at a level lower than that observed with PAK (Fig. 7A), suggesting
a strong contribution of bacterial flagellum in this signaling pathway. On the contrary, no
significant induction was obtained with classical ligands of TLR4 and P2Y2R, such as LPS
and ATP/UTP, respectively (Fig. 7A). Since ATP-dependent induction of IL-8 in bronchial
epithelial cells has been previously described only in association with ligands activating
TLRs (30), we tested the effect of ATP on the expression of IL-8 upon stimulation with
flagellin, which interacts with TLR5. We observed that ATP is not sufficient by itself to
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induce IL-8 expression, but it is able to potentiate the flagellin-induced one (Fig. 7B). In
order to verify that P.aeruginosa induces an autocrine loop of release of nucleotides, we
tested the effect of the ectonucleotidase apyrase in our model system. Pre-incubation of
IB3-1 cells with apyrase before exposure to P.aeruginosa PAO1 strain, reduced the
sustained increase of [Ca2+]c (Fig. 8A), the activation of PKC isoform beta (Fig. 8B and C)
and, more relevantly, the IL-8 mRNA transcription and release of IL-8 protein (Fig. 8D and
E). Interestingly, apyrase does not further reduce the P.aeruginosa-dependent IL-8
expression (Fig. 8F), suggesting that the contribution of the purinergic receptor-dependent
IL-8 expression is mainly mediated its coupling with PLCB3. This confirms a role of extra
cellular nucleotides, released upon interaction of P.aeruginosa with IB3-1 bronchial
epithelial cells, in the pro-inflammatory signaling leading to the expression and secretion of
IL-8 in our model system.
Discussion
Excessive inflammation in the lungs of patients affected by cystic fibrosis is considered a
major cause of the lung tissue damage leading to respiratory insufficiency, and therefore
anti-inflammatory drugs are included within the therapeutic pipeline of the innovative
therapies to treat or cure CF lung disease (1). The identification of novel molecular targets in
the pro-inflammatory signaling, which is firstly orchestrated by the bronchial epithelial cells
on the surface of the conductive airways, is presently of paramount importance (2).
To prioritize the relevance of specific molecules within the large series of different
receptors, kinases, phosphatases, phospholipases and adapters regulating the expression of
inflammatory genes, we chose to apply an association study between genes of the innate
immunity and the clinical progression of CF lung disease, by a genetic ranking approach. In
this respect, the aim of our genetic analysis was not to find the strongest modifier gene(s) for
CF lung disease, a task which should be presently pursued by Genome-Wide Association
Studies (GWAS) in much larger cohorts of affected individuals, but to obtain hints on the
relative clinical relevance within a list of genes selected in a family with homogeneous
pathophysiological role, e.g. the signaling network of the innate immune response to
bacteria in respiratory epithelial cells. Therefore, although the association of PLCB3 with
clinical progression of lung disease that we found here is quite modest, our genetic ranking
approach allowed us to focus on PLCB3 to demonstrate its role in regulating the expression
of IL-8 elicited by P.aeruginosa in bronchial epithelial cells.
PLCs have been shown to be implicated in different cellular responses, due to their role in
intracellular calcium homeostasis (for review see (25)). In particular, it was initially
proposed that the PLCB3 isoform is involved in signal transduction triggered by hormones,
growth factors and neurotransmitters (31). As far as its role in inflammatory processes is
concerned, PLCB3 has been investigated in the context of leukocyte chemotaxis (32). PLC
beta2- and beta3-dependent rise in intracellular calcium has been shown to regulate T
lymphocyte chemotaxis (33). However, PLCB3-deficient neutrophils or macrophages, in
which calcium transients were blunted, did not show reduction of chemotactic activity or
migration (34, 35), suggesting that PLCB3 is required for the chemotaxis of T lymphocytes
but not neutrophils or macrophages. Because T lymphocytes infiltrate the bronchial walls of
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CF patients, these early reports established already a possible link between PLCB3 and the
progression of CF lung disease. Our findings strengthen this notion implicating PLCB3 in
regulation of IL-8 expression by bronchial epithelial cells and hence neutrophil recruitment
into the airways.
Bronchial epithelial cells do express different isoforms of PLC that could regulate
intracellular calcium homeostasis and, in particular, IB3-1 and CuFi-1 cells express
detectable transcript levels of PLC beta 1 and 4, gamma 2, delta 3 and epsilon 1, besides
PLCB3 (Supplemental Figure S2). How can we explain the specific contribution of PLCB3
in the proinflammatory signaling induced by P.aeruginosa in bronchial epithelial cells ?
Activation of gamma and epsilon isoforms is known to be dependent on tyrosine-kinase
coupled receptors, of the delta isoforms on elevation of cytosolic calcium, of the beta
isoforms on seven-membrane spanning domain receptors through GTP-binding proteins
(25). As far as we know, among the surface receptors expressed in bronchial epithelial cell
that are engaged by P.aeruginosa, TLRs and ASGM1R have not been described as coupled
to GTP-binding proteins (36). However, it has been previously shown that the interaction of
P.aeruginosa with bronchial epithelial cells induces the release of ATP in the extra cellular
milieu, which binds to the seven-membrane spanning P2Y2 purinergic receptors (12, 13).
Our results with the ectonucleotidase apyrase confirm a role of extra cellular ATP in the
[Ca2+]c increase and report for the first time the activation of PKC alpha and beta by P.
aeruginosa in an ATP-dependent manner (Fig. 8). Moreover, silencing experiments
reducing cytosolic calcium increase and activation of PKC beta confirm the involvement of
PLCB3 in the Ca2+ pathway activated by P.aeruginosa (Fig. 4 and 6). Thus, these results are
consistent with the coupling of P2Y2 purinergic receptors with PLCB3, which is known to
involve Gaq/11 heterotrimeric GTPase protein (29, 36). Because PLC beta 1 and 4 are also
able to interact with seven-membrane spanning receptors, we can not definitely restrict to
PLCB3 the role to modulate P.aeruginosa-dependent calcium transients in bronchial
epithelial cells. Interestingly, in murine macrophages it has been shown that UDP can
activate cytosolic calcium rise through purinergic receptors by using PLCB3 in parallel with
PLC beta 4, whereas other ligands, such as C5a, utilize predominantly PLCB3 (26).
Because, in our experimental model, selective silencing of PLCB3 resulted in a consistent,
but not total, reduction of intracellular Ca2+-dependent expression of IL-8, we cannot
exclude a partial contribution of the other PLC beta isoforms.
Silencing PLCB3 reduces only partially the P.aeruginosa-dependent expression of IL-8
(Fig. 1 and 2). This is not surprising at the light of the partial efficiency of PLCB3 silencing
and of the evidence that P.aeruginosa activates the inflammatory response due to its
capability to interact with multiple receptors, including TLRs and ASGM1Rs (37). Thus the
ATP–P2Y2R autocrine loop that generates intracellular Ca2+-signaling should be considered
only one of the pathways regulating IL-8 expression, in parallel with those elicited by TLRs
via MyD88-dependent signals. We observed a significant reduction of IL-8 mRNA
expression with the intracellular Ca2+ chelator BAPTA (Fig. 3), whereas direct stimulation
of IB3-1 cells with P2Y2 ligands, such as ATP or UTP, that are known to stimulate directly
cytosolic Ca2+ transients, were not sufficient to induce transcription of IL-8 mRNA (Fig.7),
as previously observed by other investigators (30). This apparent discrepancy can be
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explained observing that the addition of ATP to the TLR5/2 and ASGM1R ligand flagellin
increases IL-8 mRNA expression (Fig. 7), thus suggesting that the intracellular calcium
signaling triggered by purinergic receptors upon release of ATP, albeit not sufficient by
itself to completely activate the transcription machinery for IL-8 expression, works in
synergy with TLRs-mediated signalling. As a further evidence that Ca2+ - signaling
mediated by PLCB3 is indeed relevant to regulate IL-8 expression, we observed that
silencing of PLCB3 significantly reduced the activation of the Nuclear Factor – kB (Fig. 6),
which plays a critical role in the induction of IL-8 transcription (20, 29). Based on these and
previous findings (12, 13), we conclude that in the CF airway tract chronically infected with
P.aeruginosa, the Ca2+-dependent pathway induced by the release of nucleotides activates,
through binding to P2Y2R, PLCB3 and amplifies the innate defense signaling based upon
TLRs and ASGM1R. The cartoon reported in Fig. 9 summarizes our working hypothesis.
The biological importance of intracellular calcium homeostasis in bronchial epithelial cells
in the CF lung disease has been widely debated. For instance, it has been proposed that the
defective chloride transport due to the mutated CFTR protein can be overcome by activating
alternative Ca2+-dependent chloride channels, such as those recently identified (38, 39).
Independently of the presence of a constitutive inflammation in CF bronchial epithelial cells,
in which alteration of Ca2+ homeostasis might not play a role (39), when chronic bacterial
infection intervenes in the first decades of life, the Ca2+ signaling in the bronchial epithelial
cells greatly amplifies the recruitment and transepithelial migration of leukocytes, first of all
polymorphonuclear neutrophils (40), that are considered unwilling actors of the progressive
destruction of CF lung tissue (2). Thus, in the advanced stages of CF lung disease
characterized by chronic bacterial infection, intracellular Ca2+ signals are known to induce
endoplasmic reticulum Ca2+ store expansion leading to an overt hyper-inflammatory
phenotype, with inappropriate release of chemokines and cytokines, that amplifies the
recruitment and activation of leukocytes (41).
The inexorable decline of the lung function in patients affected by CF is presently faced with
different approaches directed towards the mutated CFTR protein, alternative chloride
channels, novel anti-inflammatory and anti-infective drugs (1). Consensus is growing on that
effective causative therapies, when available, should be initiated as soon as possible, in
order to prevent the onset of pulmonary complications. However, in patients who already
developed bacterial infection, a novel anti-inflammatory approach directed towards the
specific pathophysiology of infected CF lungs should be taken into consideration. In this
respect, PLCB3, which relevantly regulates the extra cellular nucleotide-cytosolic Ca2+
signaling axis potentiating the Toll-like Receptors signaling cascade, represents a novel
pharmacological target to attenuate the excessive recruitment of neutrophils without
completely abolishing the inflammatory response.
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Refer to Web version on PubMed Central for supplementary material.
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Silencing PLCB3 reduces P.aeruginosa-dependent expression and release of IL-8 in human
bronchial epithelial IB3-1 cells. A, Quantitative expression of PLCB3 mRNA by qRT-PCR
after transfection with PLCB3 siRNA or scrambled oligonucleotides sequences 1 and 2 for
24 hrs and subsequent infection with PAO1 (100 CFU/cell) for further 4 hrs. The mRNA
expression reported in Y-axis is relative to scrambled-treated uninfected cells. Mean ±
S.E.M. of 8 independent experiments performed in duplicate. B, Immunofluorescence signal
of PLCB3 protein in IB3-1 cells transfected with scrambled oligonucleotide sequence 1 or
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C, PLCB3 siRNA oligonucleotide sequence, in the presence of primary anti-PLCB3
antibody D, or irrelevant antibody. E, Quantification of the fluorescence signal as %
Fluorescence Arbitrary Units (F.A.U.) related to the expression of PLCB3 protein of IB3-1
cells treated with scrambled versus PLCB3 siRNA oligonucleotides. Percentual reduction of
36.8 ± 6.6 of the fluorescent signal, of 10 cells treated with PLCB3 siRNA and 10 cells
treated with scrambled oligonucleotides, respectively. F, Quantitative expression of IL-8
mRNA after transfection with PLCB3 siRNA sequence 1 and 2 or scrambled
oligonucleotides in IB3-1 cells as described for panel A. Mean + S.E.M. of 5 independent
experiments performed in duplicate. G, Effect of PLCB3 siRNA (sequence 1) on IL-8
transcription induced by flagellin (10 µg/ml) and TNF-α (50 ng/ml). Mean + S.E.M. of 3
independent experiments performed in duplicate. H, Effect of PAO1 (100 CFU/cell),
flagellin (10 µg/ml) and TNF-α (50 ng/ml) on IL-8 protein release, treated as in panel A
with PLCB3 siRNA (sequence 1) or scrambled oligonucleotide. Mean ± S.E.M. of 3
independent experiments performed in duplicate. I, Effect of PAO1 (100 CFU/cell) in IB3-1
cells transfected with PLCB3 siRNA (sequences 1 or 2) on ICAM-1, GRO-γ, IL-6 and TNF-
α mRNA transcription. Mean ± S.E.M. of 3 independent experiments performed in
duplicate.
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Silencing PLCB3 reduces P.aeruginosa-dependent expression and release of IL-8 in
polarized human bronchial CF CuFi-1 cells. A, Quantitative expression of PLCB3 mRNA by
qRT-PCR after transfection with PLCB3 siRNA sequences 1 and 2 or scrambled
oligonucleotides for 24 hrs and subsequent infection with PAO1 (100 CFU/cell) for further 4
hrs. The mRNA expression reported in Y-axis is relative to scrambled-treated uninfected
cells. Mean ± S.E.M. of 4 independent experiments performed in duplicate. B, Levels of
IL-8 mRNA in the same experiments reported in panel A. C, Release of IL-8 protein in the
same experiments reported in panel A with PLCB3 siRNA sequence 1. IL-8 protein
concentration refers to that collected from the apical side of the Transwell® insert filter.
Mean ± S.E.M. of 3 separate experiments performed in duplicate.
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Intracellular calcium chelator BAPTA inhibits the transcription of IL-8 mRNA induced by
P.aeruginosa. A, Cytosolic free Ca2+ concentration as measured with Fura-2/AM assay in
IB3-1 cells exposed to PAO1 (black trace) or with tissue culture medium alone (grey trace).
Traces are representative of 8 independent experiments. B, The intracellular Ca2+-chelator
BAPTA-AM (5 mM) was pre-incubated with IB3-1 cells for 30 min at 37°C in order to
obtain diesterification of the acetoxymethyl ester. Cells were exposed to PAO1 (100 CFU/
cell) or Tumor Necrosis Factor (TNF)-α (50 ng ml) for further 4 hrs before extraction of
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total RNA and qRT-PCR. Data are mean ± S.E.M. of 3 separate experiments performed in
duplicate. C, After pre-incubating IB3-1 cells with PLCB3 siRNA sequence 1 or scrambled
oligonucleotides for 24 hrs, BAPTA-AM was added for 30 min at 37°C, to obtain
intracellular partition and diesterification of the acetoxymethylester. Infection with PAO1
strain was performed for further 4 hrs, total RNA was extracted and IL-8 mRNA was
quantified by qRT-PCR. Data are mean ± S.E.M. of 4 separate experiments performed in
duplicate.
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Silencing PLCB3 affects the release of calcium from endoplasmic reticulum. IB3-1 cells
were pre-treated with PLCB3 siRNA sequence 1 (grey traces) or scrambled (black traces)
oligonucleotides, respectively, for 24 hrs before measuring intracellular Ca2+ transients. A,
intracellular free [Ca2+]i with Fura-2/AM assay after addition of PAO1 (100 CFU/cell), n =
8. B, Endoplasmic reticulum calcium concentration ([Ca2+]er) by endoplasmic reticulum-
targeted aequorin in the presence of 1 mM extra cellular calcium or with the addition of
histamine (His, 100 mM) for the time indicated. Luminal ER Ca2+ concentration
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measurement was 212 ± 9.52 µM in mock vs. 215 ± 5.51 µM in PLCB3 silenced cells, n =
10. C, Variation of ER calcium release kinetic upon histamine addition expressed as mM/s:
in mock 4.26 ± 0.33 vs 3.31 ± 0.13, p < 0.05, n = 10 PLCB3 silenced cells, respectively. D,
Mitochondrial calcium concentration ([Ca2+]m) by mitochondrial-targeted aequorin with the
addition of histamine, [Ca2+]m: mock 2.58 ± 0.19 µM vs. PLCB3 silenced 2.06 ± 0.23 µM, n
= 10. E, cytosolic calcium concentration ([Ca2+]c) by native aequorin with the addition of
histamine, [Ca2+]c: mock 1.65 ± 0.13 µM vs. PLCB3 silenced 1.50 ± 0.11 µM, n = 10.
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P.aeruginosa activates conventional PKC isoforms alpha and beta. Fluorescence signal of
Green Fluorescent Protein (GFP)-tagged PKC isoforms A, alpha, B, beta, C, delta and D,
zeta before and after 30 min from the addition of PAO1 (100 CFU/cell) to IB3-1 cells.
Histograms indicate the intracellular localization of PKC isoforms, as increase in
fluorescence ratio with respect to time zero (ratio of translocation from cytosol to plasma
membrane or nucleus) as mean ± S.E.M. for at least 7 single cells (see Materials and
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Methods). Averaging of % ratio: PKCα +76% ± 11.6; PKCβ +114% ± 11.4; PKCδ +5% ±
0.8; PKCζ +4% ± 1.0.
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Silencing PLCB3 reduces the activation of PKC-beta and of NF-kB p65 induced by
P.aeruginosa. A, IB3-1 cells were transfected with PLCB3 siRNA sequence 1 or B,
scrambled oligonucleotides 24 hrs before the addition of PAO1 (100 CFU/cell). Images refer
to representative experiments of expression of GFP-tagged PKC isoform beta, before and 30
min after exposure to PAO1. The PKC activator phorbol myristate acetate (PMA, 400 nM)
was added to cells not responding to PAO1-dependent translocation, as an internal control.
Translocation of PKC-beta from cytosol to membrane was observed in 56.1% of the IB3-1
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cells transfected with scrambled sequence (on 57 scrambled cells 32 cells presented PKC-
beta traslocation) and in 12.0% (on 25 PLCB3 siRNA cells only 3 cells presented PKC-beta
traslocation) of cells transfected with PLCB3 siRNA sequence. The histograms indicate the
intracellular localization of PKCβ, expressed as ratio of translocation from cytosol to plasma
membrane. Averaging of % ratio in silenced cells: after 30 min to PAO +1% ± 10.3 and
after treatment with PMA +275% ± 21.5 respect to time zero; in mock cells: after 30 min to
PAO +78% ± 24.6. C, IB3-1 cells were pre-incubated with the PKCs inhibitor
bisindolylmaleimide (BIM)-I (2 µM) for 30 mins and infected with PAO1 or stimulated with
TNF-α for further 4 hrs, before quantitation of IL-8 mRNA by qRT-PCR. Data are mean ±
S.E.M. of 3 separate experiments performed in duplicate. D, Activation of NF-kB p65 in
IB3-1 cells transfected with either PLCB3 siRNA sequence 1 or scrambled oligonucleotide
for 24 hrs before exposure to PAO1 (100 CFU/cell) or solvent alone in a lapse of time
ranging from 1 to 4 hrs. Absorbance at 450 nm wavelength is proportional to the activation
of NF-kB p65, as performed with the TransAM NF-kB p65 Activation Assay kit. Data are
mean ± S.E.M. of 4 independent experiments performed in duplicate.
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ATP is not sufficient to activate IL-8 mRNA transcription but acts in synergy with TLR-
dependent signaling. A, IB3-1 cells were exposed to the P.aeruginosa laboratory strains
PAO1, PAK or PAK FliC (100 CFU/cell), to flagellin (10 mg/ml) and pilin (10 mg/ml)
purified from PAK recombinant cells, to lipopolysaccharide (LPS, 10 mg/ml), to ATP and
UTP (1 mM) or to TNF-α (50 ng/ml) for 4 hrs before extraction of total RNA and
measurement of IL-8 mRNA. B, Similarly to panel A, IB3-1 cells were exposed to ATP or
flagellin alone, or to both stimulants together, for 4 hrs before extraction of total RNA and
measurement of IL-8 mRNA. Mean ± S.E.M. of 3 independent experiments performed in
duplicate.
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The ectonucleotidase apyrase affects calcium signaling and IL-8 expression induced by
P.aeruginosa. The ectonucleotidase apyrase (3 U/ml) was added to IB3-1 cells 2 hrs before
and again together with the addition of PAO1 for further 4 hrs. A, Cytosolic Ca2+ transients
by Fura-2/AM assay in IB3-1 cells exposed to PAO1 treated with apyrase (grey trace) or
solvent alone (untreated, black trace), n = 8. B, Activation of PKC isoform beta in IB3-1
cells exposed to PAO1 treated either with apyrase or C, solvent alone (untreated). The PKC
activator phorbol myristate acetate (PMA, 400 nM), a Ca2+-independent DAG-like agonist,
Bezzerri et al. Page 30






















was added to cells not responding to PAO1-dependent translocation, as an internal control.
Translocation of PKC-beta from cytosol to membrane was observed in 56.1 % of the IB3-1
cells mock treated and in 25.9 % of cells treated with apyrase (on 27 pre-treated apyrase
cells only 7 cells presented PKC-beta traslocation, after PAO1 exposition). Histograms show
the intracellular localization of PKCβ isoform: averaging of % ratio in apyrase-treated cells:
after 30 min to PAO +8% ± 2.6 and after PMA +89% ± 16.0 respect to time zero; in
untreated cells: after 30 min to PAO +61% ± 15.2. D, IL-8 mRNA transcription was
quantitated in IB3-1 cells exposed to PAO1 treated either with apyrase or solvent alone. E,
As for panel C, the release of IL-8 protein was measured by ELISA in IB3-1 cells treated
with apyrase or solvent alone. Mean ± S.E.M. of 3 independent experiments performed in
duplicate. F, Apyrase (3 IU/ml) was incubated for 2 hrs at 37°C after a pre-incubation of 24
hrs with PLCB3 siRNA sequence 1 or scrambled oligonucleotides in IB3-1 cells. A further 4
hrs infection with PAO1 strain was performed and IL-8 transcription was quantified by
qRT-PCR. Data are mean ± S.E.M. of 3 separate experiments performed in duplicate.
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Model of cooperation of PLCB3 in the P.aeruginosa-dependent signaling in bronchial
epithelial cells. The cartoon depicts the signaling pathways elicited by TLRs/MyD88 (A)
and P2Y2R/PLCB3 (B), based on previous reports from other investigators and the results
presented here. A, Binding of P.aeruginosa surface components (flagellin, pilin) with TLR5
and TLR2 triggers a MyD88-dependent proinflammatory signaling cascade, eventually
leading to nuclear translocation of NF-kB, which is a critical transcription factor for the
expression of IL-8 gene, together with AP-1 and CHOP. TLRs/MyD88 pathway is sufficient
to promote transcription of IL-8 gene. Besides exerting this direct effect, P.aeruginosa
induces the extra cellular release of ATP, possibly via a cooperative interaction of TLR5,
TLR2 and ASGM1R. B, Extra cellular ATP binds to P2Y2R that activates PLCB3 through
Bezzerri et al. Page 32






















the Gaq,11 heterotrimeric GTPase protein. By degrading PIP2, PLCB3 promotes IP3 release
and DAG formation. IP3 triggers Ca2+ release from intracellular stores and rise of [Ca2+]c,
together with DAG, promotes intracellular translocation of conventional PKC isoforms
alpha and beta, which ultimately cooperate in activation of NF-kB. The P2Y2R/PLCB3
pathway is not sufficient to induce IL-8 transcription by itself but strongly act in synergy
with the TLR/MyD88 signaling cascade.
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